natgillin/translations-raw huggingface dataset:
During the spinning process, the slubbings are broken down into individual fibres and laid at right angles around the continuous core filament and friction-bonded therewith. 
Za vrijeme postupka predenja skupine vlakana se lome u pojedinačna vlakna i polažu se pod pravim kutom oko kontinuirane središnje niti i frikcijski se vežu s njom.
and wherein the terms "lower alkyl", "lower alkoxy", "mono- or di-lower alkylamino", and "lower alkenyl" have the following meanings: 
pri čemu izrazi “niži alkil”, “niži alkoksi”, “mono- ili di-niži alkilamino”, i “niži alkenil” imaju sljedeća značenja:
creating a wet area within said module (2) by providing waterproof layers on the interior sides of the walls and the floor of said compartment, 
(ili) stvarajući mokro područje unutar navedenog modula (2) pružanjem vodootpornih slojeva s unutarnjih strana zidova i poda navedenog odjeljka,
The composition of claim 1 wherein said pharmaceutically acceptable salt is a hydrochloride salt, hydrobromide salt, methanesulfonate, toluenesulfonate, acetate, fumarate, sulfate, bisulfate, succinate, citrate, phosphate, maleate, nitrate, tartrate, benzoate, biocarbonate, carbonate, sodium hydroxide salt, calcium hydroxide salt, potassium hydroxide salt, tromethamine(Tris) salt, or mixtures thereof. The composition of claim 5 wherein said pharmaceutically acceptable salt is a hydrochloride salt, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate, or mixtures thereof. 
Sastav prema zahtjevu 1, naznačeno time da je spomenuta farmaceutski prihvatljiva sol hidrokloridna sol, hidrobromidna sol, metan sulfonat, toluensulfonat, acetat, fumarat, sulfat, bisulfat, sukcinat, citrat, fosfat, maleat, nitrat, tartrat, benzoat, bikarbonat, karbonat, sol natrijevog hidroksida, sol kalcijevog hidroksida, sol kalijevog hidroksida, sol trometamina(Tris), ili mješavine istih, poželjno hidrokloridna sol, metan sulfonat, toluensulfonat, acetat, sukcinat, citrat, maletat, tartrat, ili mješavina istih, a najpoželjnije sol acetata.
The pharmaceutical composition of clause 2 or clause 3, wherein the amount of the corresponding sulfoxide does not increase by more than 0.5% by weight of the initial amount of montelukast after storage at about 40°C and about 75% relative humidity for 3 months. 
Farmaceutska kompozicija prema patentnom zahtjevu 2 ili 3, naznačena time što se količina odgovarajućeg sulfoksida ne povećava za više od 0.5 težinskih % od početne količine montelukasta poslije čuvanja na oko 40*C 1 oko 75% relativne vlažnosti u trajanju od 3 mjeseca,
Colour intensity (610) A 
Intenzitet boje (610) A
The present invention is even directed to a method of using ground quartz obtained from naturally occurring quartz in combination with glass fibers, melamine cyanurate and optionally titanium dioxide for improving at least one property of compositions based on polyamides, such as PA 6 or PA 66 in relation to heat resistance, flame retardancy in the glow wire test to IEC60695-2-12 and isotropic shrinkage characteristics. 
Uporaba kvarcnog brašna dobivenog iz prirodnog kvarca u kombinaciji sa staklenim vlaknima, melamin cijanuratom i po izboru titanijevim dioksidom za poboljšanje svojstava vezanih uz otpornost na toplinu, usporavanje plamena pri ispitivanju žicom prema IEC60695-2-12 i karakteristike izotropnog skupljanja pripravaka bazirane na PA 6 ili PA 66.
The APPLI-PRO™ system available from Pioneer Hi-Bred International, Des Moines, Iowa, and disclosed at U.S. Ser. 
APPLI-PROTM sustav koji se može nabaviti od Pioneer Hi-Bred International, Des Moines, Iowa, SAD, i koji je opisan u U.S. Seial No.
Blend in the soft butter to make a soft dough. 
Miješati zajedno s omekšanim maslacem da se dobije meko tijesto.
preparation of #1 Extract: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis and Semen Cassiae are mixed, extracted by using heating refluxing for 2 times with 4 fold of 70% ethanol, the first time for 2 hours and the second time for 1 hour, and filtered to remove the impurities; and the ethanol is recovered and concentrated until the relative density is 1.300∼1.310 at 74∼76°C to give #1 Extract for later use; 
Priprema ekstrakta br. 1: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis i Semen Cassiae se pomiješaju, ekstrahiraju se uz refluks i zagrijavanje s 2 do 4 puta većom količinom 70% etanola, prvi put 2 sata, a drugi put 1 sat, i filtriraju kako bi se uklonile nečistoće; i etanol se izdvaja i koncentrira do relativne gustoće 1.300 ± 1.310 na 74 do 76°C da se dobije ekstrakt br. 1 za kasniju uporabu;
The process of claim 2, wherein the resid hydrocarbon fraction comprises hydrocarbons with a normal boiling point of at least 480°C. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da ostatak ugljikovodične frakcije sadržava ugljikovodike s uobičajenim vrelištem od najmanje 480 °C.
The compound according to Claim 5, wherein R3 represent phenyl which may be substituted with a group selected from a group consisting of 
Tvar u skladu s patentnim zahtjevom 2, pri čemu predstavlja fenil koji može biti supstituiran grupom odabranom iz grupe koja se sastoji od
A fast disintegrating dosage form according to any of claims 1 to 6, wherein the functionalized natural or synthetic calcium carbonate has an intra-particle porosity determined as the pore volume per unit particle volume within the range of from 20 vol.% to 99 vol.%, preferably form 30 vol.% to 80 vol.%, more preferably from 40 vol.% to 70 vol.%, .-%, most preferably from 50 vol.% to 65 vol.%. calculated from mercury porosimetry measurement. 
Brzo razgradiv oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što funkcionalizirani prirodni ili sintetski kalcijev karbonat ima poroznost unutar čestica određenu kao volumen pora po jedinici volumena čestica u rasponu od 20 vol.% do 99 vol.%, poželjno od 30 vol.% do 80 vol.%, poželjnije od 40 vol. % do 70 %, . -%, najpoželjnije od 50 vol.% do 65 vol.%. izračunato iz mjerenja porozimetrije žive.
A combination according to claim 1 or 2 characterised in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. A product comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvod koji sadrži (a) P2 agonist kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 7 i (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od bolesti dišnih putova koje su definirane u patentnom zahtjevu 11 ili 12.
The hollow spherical glass particle of any one of claims 1 to 6, wherein the hollow spherical glass particle has melting temperature of at least 1200°C. 
Å uplja sferična staklena čestica sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu šuplja sferična staklena čestica ima točku topljenja od najmanje 1200%C.
Identification assembly according to any of the preceding claims, wherein the second laser produced image (21) is formed by laser engraving and the amount of the laser energy absorbed by the adjacent surface (13, 14) is at least 10 times higher than the amount of laser energy absorbed in the second image area (20). 
Sklop za identifikaciju prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je druga laserski producirana slika (21) uobličena laserskim utiskivanjem a količina laserske energije koju apsorbira susjedna površina (13, 14) je barem 10 puta veća od količine laserske energije apsorbirane u drugom slikovnom području
The antibody or antigen-binding fragment thereof of claim 1, wherein, the antibody or antigen-binding fragment thereof is an antagonist of Sp35 mediated neurite outgrowth inhibition, an antagonist of Sp35-mediated myelination inhibition, or an antagonist of Sp35-mediated oligodendrocyte differentiation inhibition. 
Antitijelo ili antigen vezujući fragment istog iz zahtjeva 1, pri čemu je antitijelo ili antigen vezujući fragment istog antagonist Sp35-posredovane inhibicije izrastanja neurita, antagonist Sp35-posredovane inhibicije mijelinizacije, ili antagonist Sp35-posredovane inhibicije diferencijacije oligodendrocita.
The position of the pressure line 22 in the lid 5 and of the CO2 cartridge 17 are such that when the lid 5 is hinged closed, the reservoir connector 23 and the pressure medium feed connector 24 connect to the CO2 cartridge 17 and to the pressure medium feed opening 21 in the container, respectively. 
Položaj tlačnog voda 22 na poklopcu 5 i CO, patrone 17 su takvi da kad je šarka poklopca 5 u zatvorenom položaju, priključak rezervoara 23 i priključak napajanje tlačnim medijem 24 se spajaju na CO; patronu 17, odnosno na otvor napajanja tlačnim medijem 21 na spremniku.
The method of claim 6, wherein the second selected component consists essentially of soft plastic and fiber. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time, ća se druga odabrana komponenta sastoji u biti od mekanog plastičnog materijala 1 vlakana.
wherein the matrix comprises (i) at least one gum and (ii) at least one non-crystallising sugar or non-crystallising sugar alcohol; wherein the matrix comprises, by weight, from 40-90% of gum component (i), and from 60-10% of the non-crystallising sugar or non-crystallising sugar alcohol component (ii); and wherein the lozenge dissolves or disintegrates gradually. 
(b) aktivno sredstvo; 1 (c) vodu pri čemu matriks sadrži (1) najmanje jednu gumu i (ii) najmanje jedan ne-kristalizirajući šećerni alkohol, pri čemu je navedeni matriks pripremljen pomoću postupka koji obuhvaća korak zagrijavanja i miješanja kombinacije gume 1 šećerne komponente u vodi, i gdje ta tableta-pastila sadrži manje od 10 mas,% saharoze.
A process for pre-treating propolis comprising at least one allergenic substance of general formula (1) 
PATENTNI ZAHTJEVI Postupak za predtretiranje propolisa obuhvaća najmanje jednu alergenu tvar opće formule (1)
Y is a bond or CH2; and R is an optionally substituted hydroxy group, or a salt thereof in combination with a dipeptidyl peptidase IV inhibitor, an insulin preparation, a PPAR function modulator, an a-glucosidase inhibitor, a biguanide, a sulfonylurea, mitiglinide or calcium salt hydrate thereof or nateglinide. 
Y je veza ili CH2; i R je opcijski supstituirana hidroksi-skupina, ili njegova sol u kombinaciji s inhibitorom dipeptidil peptidaze IV, pripravkom inzulina, funkcijskim modulatorom za PPAR, inhibitorom a-glukozidaze, bigvanidom, sulfonilureom, mitiglinidom ili s njegovom soli kalcijevog hidrata ili nateglinidom.
1 according to the first embodiment (hybrid system including the line through which LNG is compressed by the high pressure pump 120 and supplied as fuel to the propulsion system, and the line through which BOG is compressed by the compressor 150 and supplied as fuel to the propulsion system) and the liquefied gas treatment system illustrated in FIG. 2 according to the second embodiment. Although not illustrated, according to the present invention, it is obvious that the liquefied gas treatment systems illustrated in FIGS. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor uključuje prvi kompresor (13a) i drugi kompresor (13b), gdje se prva struja se grana u drugu struju i treću struju nakon prolaska kroz prvi kompresor. Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se treću struju dodatno komprimira u drugom kompresoru (13b) i šalje u izmjenjivač topline (21).
at least one pipeline pressure device according to one of the preceding claims for reducing, by driving the endless conveyor members, tensile forces on the conveyor pipeline during drawing inward into the drilled-out shank. 
najmanje jedan cjevovodni tlačni uređaj (1), prema jednom od prethodnih zahtjeva, za smanjenje, pogonjenim beskonačnim transportnim članovima (5), vlačne sile na transportnom cjevovodu (6) za vrijeme uvlačenja u izbušeni provrt (10).
Procedure according to claims 6 or 7, wherein the acidification is carried out by adding to the culture at least one acidifying agent selected from the group consisting of CO2, mixture of CO2 and air, strong or weak acids or any combination thereof. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se zakiseljavanje provodi dodavanjem u kulturu najmanje jedno sredstvo za zakiseljavanje, koje se bira iz skupine koju čine CO2, smjesa CO2 i zraka, jake ili slabe kiseline ili bilo koja njihova kombinacija.
using an encoding scheme to transmit payload data at the higher data rate; and locating a representation of the encoding scheme in the frame before the transmission of the payload data at the higher data rate. 
uporaba kodne sheme u svrhu prijenosa skupova korisničkih informacija (36) uz veću podatkovnu brzinu; i lociranje predstavljanja kodne sheme u okviru prije izvršenja prijenosa skupova korisničkih informacija (36) uz veću podatkovnu brzinu.
The method of any of the preceding claims, wherein after the estimation of the GoP-pattern a further frame type classification is performed, wherein every set of consecutive B-frames between two P-frames that consists of at least 3 B-frames is further examined as to whether the frame sizes according to the output of step a) at those positions in said sets that may contain reference B-frames are significantly larger than at all the other positions of B-frames in said sets, wherein, if this is the case for an adequate number of said sets of B-frames in the array of frame sizes, said frames are indeed assumed to be reference B-frames and the estimated GoP-structure is assumed to be a GoP-structure of a so called hierarchical coding sequence. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se nakon procjenjivanja uzorka GoP-a provodi daljnje klasificiranje tipova kadrova, gdje se svaki podskup uzastopnih B-kadrova između dva P-kadra dodatno ispituje je li omjer veličina kadrova na položajima u navedenom podskupu koji predstavlja referentne B-kadrove i veličina kadrova na svim drugim položajima veći od granične vrijednosti, koja je veća od 1, te što, ako je to slučaj za statistički značajan broj navedenih podskupova B-kadrova u matrici veličina kadrova, za navedene kadrove se zatim pretpostavlja da su referentni B-kadrovi, a za procijenjenu strukturu GoP-a se pretpostavlja da je struktura GoP-a tzv. hijerarhijskog kodnog niza.
The method according to Claim 1 wherein the polycondensation step, comprising a melt phase and a solid state phase, is conducted at a temperature of from 260°C to 290°C for the melt phase and a temperature of from 190°C to 230 °C for the solid state phase. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se korak polikondenzacije sastoji od faze taljenja i faze krutog stanja, izvodi se pri temperaturi od 260°C do 290°C u fazi taljenja i na temperaturi od 190°C do 230°C u fazi krutog stanja.
Use according to any one of the preceding claims, characterized in that prior to 2-((1-methylpropyl)amino)ethanol addition, said suspension has a temperature of between 5 and 100°C, preferably of between 35 and 85°C, and more preferably of between 45 and 75°C. Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, preferably of from 1000 to 5000 mg, and more preferably of 1300 to 2000 mg, per liter of the aqueous phase of said suspension. 
10. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je prije dodavanja 2-((1- metilpropil)amino)etanola, navedena suspenzija temperature između 5 1 100%, poželjno između 35 1 85"C, poželjnije između 45 i 75%C. 11.Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu suspenziju u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene suspenzije.
converting compound (VII) to compound (X). 
P konverziju spoja (VII) do spoja (2).
An analytical sample of the named compound was recrystallized from hexane (m.p. 
Analitički uzorak imenovanog spoja rekristalizira se iz heksana (tt.
The anti-CD20 antibody formulation for use according to claim 1, the formulation comprising ofatumumab in the concentration range of 50-300 mg/mL, 50 mM sodium acetate, mM sodium chloride, 1% arginine free base, 0.05 mM EDTA, 0.02% polysorbate 80, and adjusted to pH 5.5. 
Formulacija protutijela anti-CD20, naznačena time, da obuhvaća ofatumumab u rasponu koncentracije od 20 do 300 mg/mL, pri čemu formulacija nadalje obuhvaća 50 mM natrijevog acetata, 51 mM natrijevog klorida, 1% slobodne baze arginina, 0,05 mM EDTA, 0,02% polisorbata 80, i namještena je na pH-vrijednost od 5,5.
The method of embodiment 637, wherein said autoactivation step is performed in the supernatant. The method of embodiment 638, which further comprises the step of purifying the expressed protein. The method of any one of embodiments 627 to 639, wherein subjecting the recombinant autoactivated type I proelastase protein to autoactivation conditions comprises raising the pH of a solution containing the recovered protein. 
(e) stanica domaćina je kultivirana u kompleksnom mediju, i korak oporavljanja autoaktivacijskog proteina proelastaze obuhvaća oporavljanje supernatanta iz kulture stanice domaćina 1 opcionalno dalje obuhvaća oporavljanje autoaktivacijskog proteina proelastaze iz supernatanta. Metoda prema patentnom zahtjevu 10, koji dalje obuhvaća podvrgavanje oporavljenog autoaktivacijskog proteina proelastaze u uvjete aktivacije tako da je proizveden zreli tip I protein elastaze, opcionalno naznačena time da:
The humanized antibody or antibody fragment of any one of claims 1 to 6 for use in a diagnostic assay. 
Antitijelo ili fragment antitijela prema patentnim zahtjevima 1 do 12 za uporabu u postupku za liječenje kancera. 9 e
Floors in the building are preferably made by placing and interconnecting lightweight, heat insulating floor elements, supporting them if necessary, and pouring structural fill-material, such as concrete or the like, onto the floor elements to form the floor. 
Podni elementi bit će po mogućnosti izrađeni na način da se postave međusobno povezani, lagani, toplinski izolirajući podni elementi po potrebi poduprti, i zaliveni građevnim materijalom za ispunjavanje kao što je beton ili tome slično, preko podnih elemenata kako bi se oblikovao pod.
An oligonucleotide decoy, comprising a sequence having at least 85% identity with SEQ ID NO:33. The oligonucleotide decoy of claim 1, comprising a sequence having at least 90% identity with SEQ ID NO:33. 
sekvencu od SEQ ID NO:42; sekvencu koja obuhvaća barem 90% identiteta sekvence od SEQ ID NO:42 i sadrži jedno ili više mjesta spajanja faktora transkripcije; ili
Method according to any one of the claims 1 to 8 in combination with claim 2, characterized in that an Enhanced Physical Downlink Control Channel (EPDCCH) and Demodulation Reference Symbols (DM-RS) are employed instead of the Physical Downlink Control Channel (PDCCH) and regular Reference Symbols (RS) of the LTE system. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8 u kombinaciji s patentnim zahtjevom 2, naznačen time što se upotrebljava poboljšani kontrolni kanal fizičke silazne veze (Enhanced Physical Downlink Control Channel, EPDCCH) i demodulacijske referentne simbole (Demodulation Reference Symbols, DMRS) umjesto kontrolnog kanala fizičke silazne veze (Physical Downlink Control Channel, PDCCH) i normalnih referentnih simbola (Reference Symbols, RS) sustava LTE.
The edges of the inside side walls and angular walls are attached to the inside front wall. 
Rubovi unutarnjih bočnih zidova i kutnih zidova pričvršćeni su na unutarnji prednji zid.
The method of any of [1]-[8] wherein the substrate for the strand invasion system facilitates the separation of the target template duplex or the product of primer extension onto the target nucleic acid. 
Komplet iz bilo kojeg prethodnog patentnog zahtjeva pri čemu oligonukleotid olakšava odvajanje ciljnog dupleks šablona ili proizvoda produžavanja početnice na ciljnu nukleinsku kiselinu.
The total amount of the at least one dispersing agent added before grinding step c), or before and during step c), or before and during and/or after grinding step c), preferably is from about 0.01 to 1.25 wt %, more preferably 0.05 to 1 wt %, even more preferably 0.1 to 0.7 wt %, most preferably 0.3 to 0.5 wt % based on the dry weight of the mineral material. 
Postupak prema zahtjevu 4, naznačen time da ukupna količina najmanje jednog disperzijskog sredstva koja je dodana prije koraka mljevenja c), ili prije 1 tijekom koraka c), ili prije i tijekom i/ili nakon koraka mljevenja c), je od oko 0.01 do 1.25 % tež., poželjno 0.05 do 1 % tež., poželjnije 0.1 do 0.7 % tež., najpoželjnije 0.3 do 0.5 % tež. bazirano na težini suhog mineralnog materijala,
provided that when L is a group of the formula m·(n+2) is greater than or equal to 3 and less than or equal to 21. 
RDoĐO m m (n+2) je veći ili jednak 3 1 manji ili jednak 21. ili njegova farmaceutski prihvatljiva sol, pri čemu je pri čemu je 12.
In some aspects, the chimeric MHC II a polypeptide and/or the chimeric MHC II B polypeptide is operably linked to a non-human leader sequence. In one aspect, the genetically engineered non-human animal is a rodent. In one embodiment, the rodent is selected from the group consisting of a mouse and a rat. 
U glodavca 1z zahtjeva 4. ljudski dio kimernog MHC II a polipeptida čovjeka/glodavca kodira genski lanac HLADR4 a i/ili ljudski dio kimernog MHC II f polipeptida čovjeka/glodavca kodira ljudski genski lanac HLA-DR4 (. Glodavac iz zahtjeva 1., pri čemu je glodavac miš.
administering to a mammal in need thereof a compound of Formula I, and 
primjenu spoja Formule I sisavcu kojemu je potreban, i
A process for manufacturing an insulating product based on mineral wool, the process comprising: 
Postupak za proizvodnju izolacijskog proizvoda na temelju mineralnih vlakana, koji sadrži
the chromatography method is an affinity capture chromatography method, and the reagent functionalises the chromatography medium with a protein, peptide, antibody or fragment thereof, dye, histidine, or group containing a metal cation; 
metoda kromatografije jeste metoda detekcije afiniteta, a reagens funkcionalizira sredstvo za kromatografiju proteinom, proteinom A, proteinom G, proteinom L, peptidom, antitijelom ili njegovim fragmentom, bojom, histidinom, grupom koja sadrži metalni kation ili mimetičkim ili sintetičkim ligandom koji oponaša djelovanje proteinskog liganda;
The first day of the study was considered SD1 (the first day of dosing). 
(33) Država ili organizacija podnošenja prve prijave: US
Thus, 6 ug formoterol fumarate dihydrate and 350 ug R,R-glycopyrrolate are released per actuation. 
Prema tome, 6 ug formoterol fumarat dihidrata i 350 ug R,R-glikopirolata se oslobađa po jednom aktiviranju.
Neither showed success the investigations in EAE model performed with different zinc salts given intraperitoneally or orally (Schiffer et al., (1996) J. 
Uspjeh nije postignut niti ispitivanjima u EAE modelu koji se izvodio s različitim cinkovim solima davanim intraperitonealno ili oralno (Schiffer et al., (1996), J.
fermenting a E.coli cell and wherein said E.coli cell has been transformed with a nucleic acid encoding said recombinant protein, and 
fermentiranje stanice E.coli i pri čemu je stanica E.coli transformirana nukleinskom kiselinom koja kodira spomenuti rekombinantni protein; i
Most preferably, purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. 
Najpoželjnije smjera ka pročišćavanju od najmanje jednog reda veličine, poželjnije dva 1li tri reda 1 još požljnije četiri 1li pet redova veličine.